Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor

@article{Tassev2012RetargetingNC,
  title={Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor},
  author={Dimiter V. Tassev and Ming Yu Cheng and N-Kv Cheung},
  journal={Cancer Gene Therapy},
  year={2012},
  volume={19},
  pages={84-100}
}
Advances in adoptive cell immunotherapy have led to several promising options for cancer patients. Single-chain variable fragments (scFvs) were isolated from a human phage display library by panning on recombinant human leukocyte antigen (HLA)-A2-peptide complexes. A scFv (EBNA Clone 315) specific for HLA-A2 carrying a 10 amino acid peptide (LLDFVRFMGV) derived from the Epstein–Barr virus latent protein EBNA3C was fully characterized. EBNA Clone 315 displayed exquisite specificity toward its… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

Advantages and applications of CAR-expressing natural killer cells

  • Front. Pharmacol.
  • 2015
VIEW 5 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Immunotherapy for Pediatric Malignancies

  • Springer International Publishing
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.

  • Translational research : the journal of laboratory and clinical medicine
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

Engineering Natural Killer Cells for Cancer Immunotherapy.

  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 74 REFERENCES

- associated antigen - specific cytotoxic CD 8 + T - cell responses in patients with chronic lymphocytic leukemia

RJ O’Reilly, T Dao, G Koehne, D Scheinberg, E Doubrovina
  • 2010

Similar Papers

Loading similar papers…